Filing Details
ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) filed a Form 8-K with the Securities and Exchange Commission on August 18, 2026, disclosing a material event.
8k filedNASDAQ:ONCY
ONCOLYTICS BIOTECH INC (ONCY) Reports Material Event to SEC
ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) filed a Form 8-K with the Securities and Exchange Commission on August 18, 2026, disclosing a material event.
At publication ·
What changed
ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Oncolytics Biotech Inc filed a Form 8-K with the SEC on August 18, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock trades at $0.84 per share with a market capitalization of $100.1 million as a healthcare company.
- Form 8-K filings are used to report material events between regular quarterly or annual reports, which can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
ONCOLYTICS BIOTECH INC's stock currently trades at $0.84 with a market capitalization of $100.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ONCOLYTICS BIOTECH INC's stock.
All SEC filings for ONCOLYTICS BIOTECH INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ONCY Stock Page
Frequently Asked Questions
Where can I read ONCY's SEC filings?
Browse all filings on our ONCY SEC filings page.
What types of SEC filings does ONCOLYTICS BIOTECH INC file?
Public companies like ONCOLYTICS BIOTECH INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Loading related coverage…